University of Pittsburgh Innovation Institute Highlights Duo Oncology’s Progress to First in Human Clinical Trials.

The NCI Nanotechnology Characterization Laboratory’s Assay Cascade Characterization Program will Provide Critical Support for Duo Oncology’s Lead Program, DUO-207.

Granted US Patent Strengthens the Intellectual Property Portfolio for Duo’s Pipeline of First-in-Class Dual-Action Therapies

Duo Oncology to Present Breakthrough DUO-207 Research at 2025 ASCO GI Conference.

NIH STTR Award Funds Additional Studies Exploring Improved Duration of Treatment with DUO-207 in Mice and Dogs.

The National Cancer Institute has selected Duo Oncology for its elite Investor Initiative Program

Galien Foundation, Dedicated to Innovation to Improve the Human Condition, Selects Duo Oncology as Nominee for Best Startup.

Drs. Song Li and Jingjing Sun, publish on novel ultrasmall precision nanomedicine.

The National Cancer Institute has Awarded Duo Oncology a Grant to Develop DUO-307

Duo Oncology is pleased to announce that the Federal Drug Administration (FDA) has granted our lead product, ultrasmall nanomedicine DUO-207, Orphan Designation for the treatment of patients with pancreatic cancer.

Dr. Song Li, founder of Duo Oncology, receives NCI award to develop chemo/immunotherapy nanomedicines.

Drs. Song Li and Jingjing Sun Publish in Materials Today on Novel Ultrasmall Nanomedicine Immunotherapy.

Trade journal Genetic Engineering and Biotechnology News (GEN) has reported on the ongoing research of Duo Oncology Founder, Dr. Song Li.